Nanocopoeia

Nanocopoeia is a U.S.-based drug delivery company founded in 2004, originating from a University of Minnesota technology license. It has evolved from a medical device coating services model to a pharmaceutical development company focused on enhancing the performance of low-solubility drugs through its nanoparticle engineering platform. With substantial investor backing, the company has built a technically accomplished team to create valuable 505(b)(2) opportunities via co-development and out-licensing partnerships. Its core value proposition lies in improving bioavailability and reducing product defects to address significant unmet needs in drug formulation.

Proprietary nanoparticle engineering and scalable manufacturing platform focused on creating macro-particles for oral-solid dosage forms to enhance drug solubility and bioavailability.

Nanocopoeia competes in the crowded drug delivery and formulation technology sector, which includes large contract development and manufacturing organizations (CDMOs), specialty pharmaceutical companies, and other nanotechnology firms. Differentiation relies on demonstrating superior scalability, bioavailability enhancement, and successful execution of the 505(b)(2) partnership model.